Jiangsu Hengrui Pharmaceuticals Co Ltd, a global pharmaceutical company focusing on scientific and technological innovation, announced on March 25 that it has entered into an exclusive license ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. Hengrui Pharma will ...

Merck's stock trades at a low valuation as investors ... drug for up to $2 billion from Chinese healthcare company Hansoh Pharma. Given how massive the obesity drug market could be, topping ...

Data on federal individual contributions downloaded from the Federal Election Commission on 02/06/2025. State and local contributions are uploaded on a rolling basis. Federal law prohibits the use of ...

Spurious drug manufacturers from other states are tarnishing the image of state’s pharmaceutical industry by using fictitious names of firms located in Himachal Pradesh. A recent case which ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd., a global pharmaceutical company focused on scientific and technological innovation, ...

(Image Credits: Pixabay ... Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.

Check out the image below, which I created and downloaded with Reve Image. It looks like a real photo of a woman engaged in some sort of conflict in a snowy setting. I know, it’s strange ...

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday ... companies in the two sectors Tuesday. For example, Merck signed a deal to license a potential blockbuster ...

The deal is expected to close in the second quarter of 2025. Jiangsu Hengrui Pharma has given Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, except in ...